Overview

A Phase 1b, Single Center, Clinical Study to Investigate the Safety and Biological Responses to Baminercept in Patients With Chronic HCV Hepatitis.

Status:
Unknown status

Trial end date:
2013-02-01

Target enrollment:

Participant gender:

Summary

Erstes Safety Trial mit Baminercept in chronischen HCV Patienten. Untersuchung des potentiell antiviralen, antiinflammatorischen Effekts sowie Modulation der hepatischen Gen-Expression. 10 Patienten, open label, 10 Wochen Therapie. Sequentielles Enrollement der ersten 4 Patienten. - Trial with medicinal product

Phase:

Phase 1

Details

Lead Sponsor:

University of Zurich

Collaborator:

PD Dr. rer. nat. Mathias Heikenwälder